Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.

Medicaid dominates coverage of Novo, Lilly weight-loss drugs

Novo Nordisk (NYSE:NVO) has begun rolling out its Wegovy weight loss drug in China at well below the price of the product in the US. A month's supply of the starter dose of Wegovy in China has been priced at 1,400 yuan ($193.27), according to Chinese financial media outlet Yicai.

Novo Nordisk launches Wegovy weight drug in China at fraction of price

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market.

Novo Nordisk has launched obesity drug Wegovy in China

Vertex Pharmaceuticals

3 Growth Stocks You Can Buy Right Now Without Any Hesitation

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it's unclear whether they can ramp up production enough.

Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready To Meet Demand?

Moderna

Pfizer

SPDR S&P Biotech ETF

With Trump's appointment of Robert F. Kennedy Jr. as the secretary of Health and Human Services, the biotech industry has more questions than answers.

Trump Taps RFK for HHS: Time to Avoid Biotech?

AstraZeneca

BioNTech SE

Novavax

In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services.

Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head

Amgen

Terns Pharmaceuticals

Viking Therapeutics

Zealand Pharma

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr. his pick to head the Department of Health and Human Services.

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.

Novo Nordisk says it is gradually phasing out human insulin pens globally

Catalent

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matter said.

EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Novo Nordisk (NVO) is a Strong Growth Stock

Novo drug CagriSema, which combines semaglutide with cagrilintide, could help patients lose 25% of their body weight.

Novo Stock Has Been Slammed. How a New Weight-Loss Drug Could Boost Shares by 10%.

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong, with no signs of business deterioration. Despite Eli Lilly's underperformance in GLP-1 sales, Novo Nordisk's diabetes and obesity treatments, especially Ozempic and Wegovy, continue to show robust growth. Legal concerns over compounded versions of Ozempic and Wegovy exist, but I believe Novo Nordisk's brand trust and regulatory backing will mitigate long-term impact.

Novo Nordisk: Be Greedy When Others Are Fearful

The good times aren't over, but the peak of the party might be passing.

Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?

Bagsværd, Denmark, 8 November 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S' 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 750.42 per share and has been calculated as the three-day volume weighted average market price from 6 November 2024 to 8 November 2024 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results.

Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme

Bristol-Myers

The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve's interest rate cuts in September.

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks

Ensign Group

Royal Caribbean Cruises

According to a March 2023 study from the Bank of America Institute about consumer spending, seniors born in 1964 or earlier were the only age cohort in the U.S.

These 3 Stocks Are Winning Thanks to Baby Boomers

Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as underwhelming guidance for next year overshadowed strong sales growth for its popular Wegovy weight-loss drug.

Novo shares hits 9-month low as 2025 guidance underwhelms

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when launched in India, a top executive said.

Novo Nordisk expects high demand for its obesity drugs in India, says country head

Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 financial guidance.

NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View

Novo Nordisk A/S (NVO) Q3 2024 Earnings Conference Call November 6, 2024 7:00 AM ET Company Participants Jacob Martin Wiborg Rode - Head of Investor Relations Lars Fruergaard Jorgensen - President and Chief Executive Officer Camilla Sylvest - Executive Vice President and Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President and Head of North America Operations Martin Holst Lange - Executive Vice President and Head of Development Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer Conference Call Participants Richard Parkes - BNP Paribas Exane Sachin Jain - Bank of America Louise Chen - Cantor Fitzgerald Michael Nedelcovych - TD Cowen Jo Walton - UBS Richard Vosser - JPMorgan Florent Cespedes - Bernstein Martin Parkhoi - SEB Kerry Holford - Berenberg Mattias Haggblom - Handelsbanken Operator Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call.

Novo Nordisk A/S (NVO) Q3 2024 Earnings Call Transcript

After rising in premarket trading, Novo Nordisk's (NVO) U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weight-loss drugs Ozempic and Wegovy.

Novo Nordisk Stock Slips as Sales Grow Less Than Expected

Novo Nordisk stock inched down Wednesday after the drugmaker's weight-loss drug beat forecasts, but sales of its diabetes behemoth missed. The post Novo Nordisk Dips After Tightening Its Outlook As Wegovy Beats, But Ozempic Misses appeared first on Investor's Business Daily.

Novo Nordisk Dips After Tightening Its Outlook As Wegovy Beats, But Ozempic Misses

Novo Nordisk's sales growth next year could be in the high teens in percentage terms, Chief Financial Officer Karsten Munk Knudsen said on an analyst call following the release of third-quarter earnings on Wednesday.

Novo Nordisk CFO says 2025 sales could see high-teens percentage growth

Novo Nordisk's (NVO) U.S.-listed shares rose Wednesday morning as it reported better third-quarter profits than expected, though sales of its drugs including popular weight-loss treatments Ozempic and Wegovy grew less than expected.

News for Novo Nordisk Stock (NVO)